Similarly, ILD was observed in PRMT5/CFA-treated mice, exhibiting extensive inflammatory infiltration and diffuse fibrosis, with remarkably increased Ashcroft score than Veh/CFA-treated control mice (figure 6D,E). Here, PRMT5 is linked to interstitial lung disease.